Clinical Trial Update: Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating temsirolimus and bryostatin-1 in patients with unresectable or metastatic solid tumors, including recurrent melanoma and renal cell car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• Bryostatin-1 (bryostatin-1)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Recurrent Renal Cell Cancer | Phase 1 | Status: COMPLETED